Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in hepatocellular carcinoma

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Zheng, Tongsen ^a   Yin, Dalong ^a   Lu, Zhaoyang ^a   Wang, Jiabei ^a   Li, Yuejin ^a   Chen, Xi ^a   Liang, Yingjian ^a   Song, Xuan ^a   Qi, Shuyi ^a   Sun, Boshi ^a   Xie, Changming ^a   Meng, Xianzhi ^a   Pan, Shangha ^a   Liu, Jiaren ^b   Jiang, Hongchi ^a   Liu, Lianxin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Arsenic trioxide resistance; Hepatocellular carcinoma; Metastasis; Nutlin 3; p53 mutation; p73

Indexed keywords

ARSENIC TRIOXIDE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MUTANT PROTEIN; NERVE CELL ADHESION MOLECULE; NUTLIN 3; PROTEIN P53; PROTEIN P73; SMALL INTERFERING RNA; VIMENTIN; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; IMIDAZOLE DERIVATIVE; NUCLEAR PROTEIN; ORGANOARSENIC DERIVATIVE; OXIDE; PIPERAZINE DERIVATIVE; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; CANCER CELL LINE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRUS INFECTION; LIVER CELL CARCINOMA; LUNG METASTASIS; MOUSE; MTT ASSAY; NONHUMAN; PROTEIN DEGRADATION; THERAPY EFFECT; WESTERN BLOTTING; ANIMAL; CANCER TRANSPLANTATION; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LIVER NEOPLASMS; LUNG NEOPLASMS; METABOLISM; MUTATION; NUDE MOUSE; PATHOLOGY; SECONDARY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENICALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; LIVER NEOPLASMS; LUNG NEOPLASMS; MICE; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; NUCLEAR PROTEINS; OXIDES; PIPERAZINES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84902104235     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-133     Document Type: Article

References (24)

1. Shao QS, Ye ZY, Ling ZQ, Ke JJ. Cell cycle arrest and apoptotic cell death in cultured human gastric carcinoma cells mediated by arsenic trioxide. World J Gastroenterol 2005, 11(22):3451-3456.
2. Subbarayan PR, Lima M, Ardalan B. Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic colorectal carcinoma: a clinical experience. Acta Oncol 2007, 46(4):557-561. 10.1080/02841860601042456, 17497326.
3. Vahter M. Mechanisms of arsenic biotransformation. Toxicology 2002, 181-182:211-217.
4. Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL, Yang CH. Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Invest New Drugs 2007, 25(1):77-84.
5. Chen X, Zhang M, Liu LX. The overexpression of multidrug resistance-associated proteins and Gankyrin contribute to arsenic trioxide resistance in liver and gastric cancer cells. Oncol Rep 2009, 22(1):73-80.
6. Schläwicke Engström K, Broberg K, Concha G, Nermell B, Warholm M, Vahter M. Genetic polymorphisms influencing arsenic metabolism: evidence from Argentina. Environ Health Perspect 2007, 115(4):599-605. 10.1289/ehp.9734, 1852682, 17450230.
7. Kala SV, Neely MW, Kala G, Prater CI, Atwood DW, Rice JS, Lieberman MW. The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. J Biol Chem 2000, 275(43):33404-33408. 10.1074/jbc.M007030200, 10938093.
8. Soussi T. p53 mutations and resistance to chemotherapy: a stab in the back for p73. Cancer Cell 2003, 3(4):303-305. 10.1016/S1535-6108(03)00081-3, 12726854.
9. Momeny M, Zakidizaji M, Ghasemi R, Dehpour AR, Rahimi-Balaei M, Abdolazimi Y, Ghavamzadeh A, Alimoghaddam K, Ghaffari SH. Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-XL and survivin. Med Oncol 2010, 27(3):833-842. 10.1007/s12032-009-9294-9, 19763917.
10. Lau LM, Nugent JK, Zhao X, Irwin MS. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene 2008, 27(7):997-1003. 10.1038/sj.onc.1210707, 17700533.
11. Selivanova G, Ivaska J. Integrins and mutant p53 on the road to metastasis. Cell 2009, 139(7):1220-1222. 10.1016/j.cell.2009.12.016, 20064366.
12. Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol 2013, 15(1):2-8.
13. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303(5659):844-848. 10.1126/science.1092472, 14704432.
14. Michaelis M, Rothweiler F, Klassert D, von Deimling A, Weber K, Fehse B, Kammerer B, Doerr HW, Cinatl J. Cinatl: reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist Nutlin-3. Cancer Res 2009, 69(2):416-421. 10.1158/0008-5472.CAN-08-1856, 19147553.
15. Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH, Wang Q, Zambetti GP, Schuetz JD. Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 2001, 276(42):39359-39367. 10.1074/jbc.M103429200, 11483599.
16. Secchiero P, Bosco R, Celeghini C, Zauli G. Recent advances in the therapeutic perspectives of Nutlin-3. Curr Pharm Des 2011, 17(6):569-577. 10.2174/138161211795222586, 21391907.
17. Yan W, Zhang Y, Zhang J, Liu S, Cho SJ, Chen X. Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression. J Biol Chem 2011, 286(20):17478-17486. 10.1074/jbc.M111.231639, 3093821, 21454520.
18. Yan W, Chen X, Zhang Y, Zhang J, Jung YS, Chen X. Arsenic suppresses cell survival via Pirh2-mediated proteasomal degradation of ΔNp63 protein. J Biol Chem 2013, 288(5):2907-2913. 10.1074/jbc.M112.428607, 3561513, 23271742.
19. Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 2007, 26(24):3473-3481. 10.1038/sj.onc.1210136, 17146434.
20. Irwin MS. Family feud in chemosensitvity: p73 and mutant p53. Cell Cycle 2004, 3(3):319-323.
21. Zauli G, Celeghini C, Melloni E, Voltan R, Ongari M, Tiribelli M, di Iasio MG, Lanza F, Secchiero P. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. Haematologica 2012, 97(11):1722-1730. 10.3324/haematol.2012.062083, 3487447, 22689683.
22. Zauli G, Voltan R, Bosco R, Melloni E, Marmiroli S, Rigolin GM, Cuneo A, Secchiero P. Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway. Clin Cancer Res 2011, 17(4):762-770. 10.1158/1078-0432.CCR-10-2572, 21106726.
23. Gao Y, Lin LP, Zhu CH, Chen Y, Hou YT, Ding J. Growth arrest induced by C75, a fatty acid synthase inhibitor, was partially modulated by p38 MAPK but not by p53 in human hepatocellular carcinoma. Cancer Biol Ther 2006, 5(8):978-985. 10.4161/cbt.5.8.2883, 16855382.
24. Liang Y, Zheng T, Song R, Wang J, Yin D, Wang L, Liu H, Tian L, Fang X, Meng X, Jiang H, Liu J, Liu L. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1alpha inhibition in hepatocellular carcinoma. Hepatology 2013, 12:1847-1857.